Australian Pediatricians Recognize Vaping Risks but Lack Referral Pathways for Adolescent Cessation

The Federation University study published in the Journal of Paediatrics and Child Health documented that just 20 percent of respondents provided direct cessation support and one-third arranged follow-up. Senior clinicians showed higher EVALI symptom recognition and reported fewer time barriers. Most viewed vaping as a gateway to tobacco and other substances, yet treatment pathways remain less established than for combustible cigarettes.

Context from US data shows similar gaps: a 2023 JAMA Pediatrics analysis of over 1,200 clinicians found only 28 percent routinely screened for e-cigarette use, with referral knowledge lowest in non-urban settings. Australia's findings align with patterns where recognition outpaces action, amplifying risks of nicotine dependence and respiratory injury in a population where daily vaping rates among 14-17 year olds reached 5 percent by 2023.

Resource constraints and unclear pathways explain the disconnect. Clearer protocols, integrated training, and dedicated quitlines could raise intervention rates. Next steps require national guidelines linking pediatricians to evidence-based behavioral support and nicotine replacement options validated in adolescent trials.

Evidence quality is moderate: cross-sectional design captures current knowledge but cannot establish causation or long-term outcomes; longitudinal studies tracking referral implementation are required.